MedElevator Войти в исследования
← Поиск публикаций

DOI 10.4103/singaporemedj.smj-2023-225

Медицинская библиотека · Singapore medical journal · 2024

Predictive factors for interstitial lung disease progression in a Singapore systemic sclerosis cohort: a multicentre study.

Noviani Maria, Saffari Seyed Ehsan, Teng Gim Gee, Lim Xin Rong, Chan Grace Yin Lai, Santosa Amelia, Hong Cassandra, Ng Sue-Ann, Low Andrea Hsiu Ling

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

Interstitial lung disease (ILD) in systemic sclerosis (SSc) is heterogeneous with varied progression rate. This study aimed to identify the baseline clinical characteristics associated with ILD progression within 1, 3 and 5 years of the diagnosis of ILD.

METHODS

This was a prospective, multicentre study - Systematic Sclerosis Cohort Singapore - conducted from January 2008 to February 2021, which included SSc patients with ILD diagnosed by high-resolution computed tomography. Progression of ILD was defined by forced vital capacity (FVC) decline ≥10% predicted or FVC decline 5%-9% predicted, with diffusing lung capacity of carbon monoxide decline ≥15% from the time of ILD diagnosis. Multivariable logistic and Cox regression analyses, adjusting for malignancy and treatment, were performed to determine independent risk factors of ILD progression.

RESULTS

Of 124 SSc patients with ILD, 47.6% had limited cutaneous SSc, 33.9% had diffuse SSc and 18.5% had SSc-overlap. Progression of ILD was seen in 6%, 15% and 23% of patients within 1, 3 and 5 years, respectively. After adjusting for malignancy and treatment, anti-La was associated with ILD progression within 1 year (odds ratio [OR] 6.94, 95% confidence interval [CI]: 1.14-42.2; P = 0.04) and 3 years (OR 5.98, 95% CI: 1.31-27.4; P = 0.02), and anti-Scl-70 was associated with ILD progression within 5 years (OR 2.54, 95% CI: 1.05-6.12; P = 0.04). Analysing time to ILD progression as an outcome, anti-La was significantly associated with higher risk of ILD progression (hazard ratio 3.47, 95% CI: 1.18-10.2; P = 0.02). Time to ILD progression was 1.4 years in patients with anti-La versus 6.9 years in patients without anti-La ( P = 0.02), and 4.7 years in patients with anti-Scl-70 versus 8.9 years in patients without anti-Scl-70 ( P = 0.12).

CONCLUSION

In this Asian cohort of SSc patients, autoantibodies may help to predict ILD progression rates.

Для цитирования: Noviani Maria, Saffari Seyed Ehsan, Teng Gim Gee, Lim Xin Rong, Chan Grace Yin Lai, Santosa Amelia, Hong Cassandra, Ng Sue-Ann, Low Andrea Hsiu Ling. Predictive factors for interstitial lung disease progression in a Singapore systemic sclerosis cohort: a multicentre study.. Singapore medical journal. 2024. DOI: 10.4103/singaporemedj.smj-2023-225.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.